Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)
NCT01160094
·
clinicaltrials.gov ↗
COMPLETED
Status
288
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
Treatment
Sponsor
Novartis